Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
Identifieur interne : 001091 ( Pmc/Checkpoint ); précédent : 001090; suivant : 001092Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
Auteurs : Georg Auzinger [Royaume-Uni] ; E. Geoffrey Playford [Australie] ; Christopher N. Graham [États-Unis] ; Hediyyih N. Knox [États-Unis] ; David Weinstein [France] ; Michal Kantecki [France] ; Haran Schlamm [États-Unis] ; Claudie Charbonneau [France]Source :
- BMC Infectious Diseases [ 1471-2334 ] ; 2015.
Abstract
Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.
Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources.
The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success.
European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness.
From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins.
Url:
DOI: 10.1186/s12879-015-1143-1
PubMed: 26503366
PubMed Central: 4623895
Affiliations:
- Australie, France, Royaume-Uni, États-Unis
- Angleterre, Caroline du Nord, Grand Londres, État de New York, Île-de-France
- Londres, Paris
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:4623895Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis</title><author><name sortKey="Auzinger, Georg" sort="Auzinger, Georg" uniqKey="Auzinger G" first="Georg" last="Auzinger">Georg Auzinger</name><affiliation wicri:level="3"><nlm:aff id="Aff1">King’s College Hospital, London, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King’s College Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Playford, E Geoffrey" sort="Playford, E Geoffrey" uniqKey="Playford E" first="E. Geoffrey" last="Playford">E. Geoffrey Playford</name><affiliation wicri:level="1"><nlm:aff id="Aff2">Princess Alexandra Hospital, Brisbane, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Graham, Christopher N" sort="Graham, Christopher N" uniqKey="Graham C" first="Christopher N." last="Graham">Christopher N. Graham</name><affiliation wicri:level="2"><nlm:aff id="Aff3">RTI Health Solutions, Research Triangle Park, Durham, NC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>RTI Health Solutions, Research Triangle Park, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Knox, Hediyyih N" sort="Knox, Hediyyih N" uniqKey="Knox H" first="Hediyyih N." last="Knox">Hediyyih N. Knox</name><affiliation wicri:level="2"><nlm:aff id="Aff3">RTI Health Solutions, Research Triangle Park, Durham, NC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>RTI Health Solutions, Research Triangle Park, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name><affiliation wicri:level="3"><nlm:aff id="Aff4">Pfizer International Operations, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><affiliation wicri:level="3"><nlm:aff id="Aff4">Pfizer International Operations, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name><affiliation wicri:level="2"><nlm:aff id="Aff5">Pfizer Inc, New York, NY USA</nlm:aff><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Pfizer Inc, New York</wicri:cityArea></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="3"><nlm:aff id="Aff4">Pfizer International Operations, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26503366</idno><idno type="pmc">4623895</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623895</idno><idno type="RBID">PMC:4623895</idno><idno type="doi">10.1186/s12879-015-1143-1</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000A97</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A97</idno><idno type="wicri:Area/Pmc/Curation">000A74</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A74</idno><idno type="wicri:Area/Pmc/Checkpoint">001091</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001091</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis</title><author><name sortKey="Auzinger, Georg" sort="Auzinger, Georg" uniqKey="Auzinger G" first="Georg" last="Auzinger">Georg Auzinger</name><affiliation wicri:level="3"><nlm:aff id="Aff1">King’s College Hospital, London, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King’s College Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Playford, E Geoffrey" sort="Playford, E Geoffrey" uniqKey="Playford E" first="E. Geoffrey" last="Playford">E. Geoffrey Playford</name><affiliation wicri:level="1"><nlm:aff id="Aff2">Princess Alexandra Hospital, Brisbane, Australia</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Graham, Christopher N" sort="Graham, Christopher N" uniqKey="Graham C" first="Christopher N." last="Graham">Christopher N. Graham</name><affiliation wicri:level="2"><nlm:aff id="Aff3">RTI Health Solutions, Research Triangle Park, Durham, NC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>RTI Health Solutions, Research Triangle Park, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Knox, Hediyyih N" sort="Knox, Hediyyih N" uniqKey="Knox H" first="Hediyyih N." last="Knox">Hediyyih N. Knox</name><affiliation wicri:level="2"><nlm:aff id="Aff3">RTI Health Solutions, Research Triangle Park, Durham, NC USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>RTI Health Solutions, Research Triangle Park, Durham</wicri:cityArea></affiliation></author><author><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name><affiliation wicri:level="3"><nlm:aff id="Aff4">Pfizer International Operations, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name><affiliation wicri:level="3"><nlm:aff id="Aff4">Pfizer International Operations, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name><affiliation wicri:level="2"><nlm:aff id="Aff5">Pfizer Inc, New York, NY USA</nlm:aff><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Pfizer Inc, New York</wicri:cityArea></affiliation></author><author><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><affiliation wicri:level="3"><nlm:aff id="Aff4">Pfizer International Operations, Paris, France</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Pfizer International Operations, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">BMC Infectious Diseases</title><idno type="eISSN">1471-2334</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.</p></sec><sec><title>Methods</title><p>Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources.</p></sec><sec><title>Results</title><p>The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success.</p></sec><sec><title>Discussion</title><p>European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness.</p></sec><sec><title>Conclusions</title><p>From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Pfaller, Ma" uniqKey="Pfaller M">MA Pfaller</name></author><author><name sortKey="Diekema, Dj" uniqKey="Diekema D">DJ Diekema</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnes, Ra" uniqKey="Barnes R">RA Barnes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tortorano, Am" uniqKey="Tortorano A">AM Tortorano</name></author><author><name sortKey="Peman, J" uniqKey="Peman J">J Peman</name></author><author><name sortKey="Bernhardt, H" uniqKey="Bernhardt H">H Bernhardt</name></author><author><name sortKey="Klingspor, L" uniqKey="Klingspor L">L Klingspor</name></author><author><name sortKey="Kibbler, Cc" uniqKey="Kibbler C">CC Kibbler</name></author><author><name sortKey="Faure, O" uniqKey="Faure O">O Faure</name></author><author><name sortKey="Biraghi, E" uniqKey="Biraghi E">E Biraghi</name></author><author><name sortKey="Canton, E" uniqKey="Canton E">E Canton</name></author><author><name sortKey="Zimmermann, K" uniqKey="Zimmermann K">K Zimmermann</name></author><author><name sortKey="Seaton, S" uniqKey="Seaton S">S Seaton</name></author><author><name sortKey="Grillot, R" uniqKey="Grillot R">R Grillot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bassetti, M" uniqKey="Bassetti M">M Bassetti</name></author><author><name sortKey="Righi, E" uniqKey="Righi E">E Righi</name></author><author><name sortKey="Costa, A" uniqKey="Costa A">A Costa</name></author><author><name sortKey="Fasce, R" uniqKey="Fasce R">R Fasce</name></author><author><name sortKey="Molinari, Mp" uniqKey="Molinari M">MP Molinari</name></author><author><name sortKey="Rosso, R" uniqKey="Rosso R">R Rosso</name></author><author><name sortKey="Pallavicini, Fb" uniqKey="Pallavicini F">FB Pallavicini</name></author><author><name sortKey="Viscoli, C" uniqKey="Viscoli C">C Viscoli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arendrup, Mc" uniqKey="Arendrup M">MC Arendrup</name></author><author><name sortKey="Fuursted, K" uniqKey="Fuursted K">K Fuursted</name></author><author><name sortKey="Gahrn Hansen, B" uniqKey="Gahrn Hansen B">B Gahrn-Hansen</name></author><author><name sortKey="Schonheyder, Hc" uniqKey="Schonheyder H">HC Schonheyder</name></author><author><name sortKey="Knudsen, Jd" uniqKey="Knudsen J">JD Knudsen</name></author><author><name sortKey="Jensen, Im" uniqKey="Jensen I">IM Jensen</name></author><author><name sortKey="Bruun, B" uniqKey="Bruun B">B Bruun</name></author><author><name sortKey="Christensen, Jj" uniqKey="Christensen J">JJ Christensen</name></author><author><name sortKey="Johansen, Hk" uniqKey="Johansen H">HK Johansen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Trick, We" uniqKey="Trick W">WE Trick</name></author><author><name sortKey="Fridkin, Sk" uniqKey="Fridkin S">SK Fridkin</name></author><author><name sortKey="Edwards, Jr" uniqKey="Edwards J">JR Edwards</name></author><author><name sortKey="Hajjeh, Ra" uniqKey="Hajjeh R">RA Hajjeh</name></author><author><name sortKey="Gaynes, Rp" uniqKey="Gaynes R">RP Gaynes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colombo, Al" uniqKey="Colombo A">AL Colombo</name></author><author><name sortKey="Nucci, M" uniqKey="Nucci M">M Nucci</name></author><author><name sortKey="Salomao, R" uniqKey="Salomao R">R Salomao</name></author><author><name sortKey="Branchini, Ml" uniqKey="Branchini M">ML Branchini</name></author><author><name sortKey="Richtmann, R" uniqKey="Richtmann R">R Richtmann</name></author><author><name sortKey="Derossi, A" uniqKey="Derossi A">A Derossi</name></author><author><name sortKey="Wey, Sb" uniqKey="Wey S">SB Wey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rocco, Tr" uniqKey="Rocco T">TR Rocco</name></author><author><name sortKey="Reinert, Se" uniqKey="Reinert S">SE Reinert</name></author><author><name sortKey="Simms, Hh" uniqKey="Simms H">HH Simms</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kett, Dh" uniqKey="Kett D">DH Kett</name></author><author><name sortKey="Azoulay, E" uniqKey="Azoulay E">E Azoulay</name></author><author><name sortKey="Echeverria, Pm" uniqKey="Echeverria P">PM Echeverria</name></author><author><name sortKey="Vincent, Jl" uniqKey="Vincent J">JL Vincent</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Rubio Terres, C" uniqKey="Rubio Terres C">C Rubio-Terres</name></author><author><name sortKey="Grau, S" uniqKey="Grau S">S Grau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cornely, Oa" uniqKey="Cornely O">OA Cornely</name></author><author><name sortKey="Bassetti, M" uniqKey="Bassetti M">M Bassetti</name></author><author><name sortKey="Calandra, T" uniqKey="Calandra T">T Calandra</name></author><author><name sortKey="Garbino, J" uniqKey="Garbino J">J Garbino</name></author><author><name sortKey="Kullberg, Bj" uniqKey="Kullberg B">BJ Kullberg</name></author><author><name sortKey="Lortholary, O" uniqKey="Lortholary O">O Lortholary</name></author><author><name sortKey="Meersseman, W" uniqKey="Meersseman W">W Meersseman</name></author><author><name sortKey="Akova, M" uniqKey="Akova M">M Akova</name></author><author><name sortKey="Arendrup, Mc" uniqKey="Arendrup M">MC Arendrup</name></author><author><name sortKey="Rikan Akdagli, S" uniqKey="Rikan Akdagli S">S Rikan-Akdagli</name></author><author><name sortKey="Bille, J" uniqKey="Bille J">J Bille</name></author><author><name sortKey="Castagnola, E" uniqKey="Castagnola E">E Castagnola</name></author><author><name sortKey="Cuenca Estrella, M" uniqKey="Cuenca Estrella M">M Cuenca-Estrella</name></author><author><name sortKey="Donnelly, Jp" uniqKey="Donnelly J">JP Donnelly</name></author><author><name sortKey="Groll, Ah" uniqKey="Groll A">AH Groll</name></author><author><name sortKey="Herbrecht, R" uniqKey="Herbrecht R">R Herbrecht</name></author><author><name sortKey="Hope, Ww" uniqKey="Hope W">WW Hope</name></author><author><name sortKey="Jensen, He" uniqKey="Jensen H">HE Jensen</name></author><author><name sortKey="Lass Florl, C" uniqKey="Lass Florl C">C Lass-Florl</name></author><author><name sortKey="Petrikkos, G" uniqKey="Petrikkos G">G Petrikkos</name></author><author><name sortKey="Richardson, Md" uniqKey="Richardson M">MD Richardson</name></author><author><name sortKey="Roilides, E" uniqKey="Roilides E">E Roilides</name></author><author><name sortKey="Verweij, Pe" uniqKey="Verweij P">PE Verweij</name></author><author><name sortKey="Viscoli, C" uniqKey="Viscoli C">C Viscoli</name></author><author><name sortKey="Ullmann, Aj" uniqKey="Ullmann A">AJ Ullmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sucher, Aj" uniqKey="Sucher A">AJ Sucher</name></author><author><name sortKey="Chahine, Eb" uniqKey="Chahine E">EB Chahine</name></author><author><name sortKey="Balcer, He" uniqKey="Balcer H">HE Balcer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kett, Dh" uniqKey="Kett D">DH Kett</name></author><author><name sortKey="Shorr, Af" uniqKey="Shorr A">AF Shorr</name></author><author><name sortKey="Reboli, Ac" uniqKey="Reboli A">AC Reboli</name></author><author><name sortKey="Reisman, Al" uniqKey="Reisman A">AL Reisman</name></author><author><name sortKey="Biswas, P" uniqKey="Biswas P">P Biswas</name></author><author><name sortKey="Schlamm, Ht" uniqKey="Schlamm H">HT Schlamm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reboli, Ac" uniqKey="Reboli A">AC Reboli</name></author><author><name sortKey="Rotstein, C" uniqKey="Rotstein C">C Rotstein</name></author><author><name sortKey="Pappas, Pg" uniqKey="Pappas P">PG Pappas</name></author><author><name sortKey="Chapman, Sw" uniqKey="Chapman S">SW Chapman</name></author><author><name sortKey="Kett, Dh" uniqKey="Kett D">DH Kett</name></author><author><name sortKey="Kumar, D" uniqKey="Kumar D">D Kumar</name></author><author><name sortKey="Betts, R" uniqKey="Betts R">R Betts</name></author><author><name sortKey="Wible, M" uniqKey="Wible M">M Wible</name></author><author><name sortKey="Goldstein, Bp" uniqKey="Goldstein B">BP Goldstein</name></author><author><name sortKey="Schranz, J" uniqKey="Schranz J">J Schranz</name></author><author><name sortKey="Krause, Ds" uniqKey="Krause D">DS Krause</name></author><author><name sortKey="Walsh, Tj" uniqKey="Walsh T">TJ Walsh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ofman, Jj" uniqKey="Ofman J">JJ Ofman</name></author><author><name sortKey="Sullivan, Sd" uniqKey="Sullivan S">SD Sullivan</name></author><author><name sortKey="Neumann, Pj" uniqKey="Neumann P">PJ Neumann</name></author><author><name sortKey="Chiou, Cf" uniqKey="Chiou C">CF Chiou</name></author><author><name sortKey="Henning, Jm" uniqKey="Henning J">JM Henning</name></author><author><name sortKey="Wade, Sw" uniqKey="Wade S">SW Wade</name></author><author><name sortKey="Hay, Jw" uniqKey="Hay J">JW Hay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Neoh, Cf" uniqKey="Neoh C">CF Neoh</name></author><author><name sortKey="Liew, D" uniqKey="Liew D">D Liew</name></author><author><name sortKey="Slavin, M" uniqKey="Slavin M">M Slavin</name></author><author><name sortKey="Marriott, D" uniqKey="Marriott D">D Marriott</name></author><author><name sortKey="Chen, Sc" uniqKey="Chen S">SC Chen</name></author><author><name sortKey="Morrissey, O" uniqKey="Morrissey O">O Morrissey</name></author><author><name sortKey="Stewart, K" uniqKey="Stewart K">K Stewart</name></author><author><name sortKey="Kong, Dc" uniqKey="Kong D">DC Kong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Quartin, Aa" uniqKey="Quartin A">AA Quartin</name></author><author><name sortKey="Schein, Rm" uniqKey="Schein R">RM Schein</name></author><author><name sortKey="Kett, Dh" uniqKey="Kett D">DH Kett</name></author><author><name sortKey="Peduzzi, Pn" uniqKey="Peduzzi P">PN Peduzzi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mills, Ej" uniqKey="Mills E">EJ Mills</name></author><author><name sortKey="Perri, D" uniqKey="Perri D">D Perri</name></author><author><name sortKey="Cooper, C" uniqKey="Cooper C">C Cooper</name></author><author><name sortKey="Nachega, Jb" uniqKey="Nachega J">JB Nachega</name></author><author><name sortKey="Wu, P" uniqKey="Wu P">P Wu</name></author><author><name sortKey="Tleyjeh, I" uniqKey="Tleyjeh I">I Tleyjeh</name></author><author><name sortKey="Phillips, P" uniqKey="Phillips P">P Phillips</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Pappas, Pg" uniqKey="Pappas P">PG Pappas</name></author><author><name sortKey="Kauffman, Ca" uniqKey="Kauffman C">CA Kauffman</name></author><author><name sortKey="Andes, D" uniqKey="Andes D">D Andes</name></author><author><name sortKey="Benjamin, Dk" uniqKey="Benjamin D">DK Benjamin</name></author><author><name sortKey="Calandra, Tf" uniqKey="Calandra T">TF Calandra</name></author><author><name sortKey="Edwards, Je" uniqKey="Edwards J">JE Edwards</name></author><author><name sortKey="Filler, Sg" uniqKey="Filler S">SG Filler</name></author><author><name sortKey="Fisher, Jf" uniqKey="Fisher J">JF Fisher</name></author><author><name sortKey="Kullberg, Bj" uniqKey="Kullberg B">BJ Kullberg</name></author><author><name sortKey="Ostrosky Zeichner, L" uniqKey="Ostrosky Zeichner L">L Ostrosky-Zeichner</name></author><author><name sortKey="Reboli, Ac" uniqKey="Reboli A">AC Reboli</name></author><author><name sortKey="Rex, Jh" uniqKey="Rex J">JH Rex</name></author><author><name sortKey="Walsh, Tj" uniqKey="Walsh T">TJ Walsh</name></author><author><name sortKey="Sobel, Jd" uniqKey="Sobel J">JD Sobel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sidhu, Mk" uniqKey="Sidhu M">MK Sidhu</name></author><author><name sortKey="Van Engen, Ak" uniqKey="Van Engen A">AK van Engen</name></author><author><name sortKey="Kleintjens, J" uniqKey="Kleintjens J">J Kleintjens</name></author><author><name sortKey="Schoeman, O" uniqKey="Schoeman O">O Schoeman</name></author><author><name sortKey="Palazzo, M" uniqKey="Palazzo M">M Palazzo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shigemi, A" uniqKey="Shigemi A">A Shigemi</name></author><author><name sortKey="Matsumoto, K" uniqKey="Matsumoto K">K Matsumoto</name></author><author><name sortKey="Ikawa, K" uniqKey="Ikawa K">K Ikawa</name></author><author><name sortKey="Yaji, K" uniqKey="Yaji K">K Yaji</name></author><author><name sortKey="Shimodozono, Y" uniqKey="Shimodozono Y">Y Shimodozono</name></author><author><name sortKey="Morikawa, N" uniqKey="Morikawa N">N Morikawa</name></author><author><name sortKey="Takeda, Y" uniqKey="Takeda Y">Y Takeda</name></author><author><name sortKey="Yamada, K" uniqKey="Yamada K">K Yamada</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Cagnoni, Pj" uniqKey="Cagnoni P">PJ Cagnoni</name></author><author><name sortKey="Walsh, Tj" uniqKey="Walsh T">TJ Walsh</name></author><author><name sortKey="Prendergast, Mm" uniqKey="Prendergast M">MM Prendergast</name></author><author><name sortKey="Bodensteiner, D" uniqKey="Bodensteiner D">D Bodensteiner</name></author><author><name sortKey="Hiemenz, S" uniqKey="Hiemenz S">S Hiemenz</name></author><author><name sortKey="Greenberg, Rn" uniqKey="Greenberg R">RN Greenberg</name></author><author><name sortKey="Arndt, Ca" uniqKey="Arndt C">CA Arndt</name></author><author><name sortKey="Schuster, M" uniqKey="Schuster M">M Schuster</name></author><author><name sortKey="Seibel, N" uniqKey="Seibel N">N Seibel</name></author><author><name sortKey="Yeldandi, V" uniqKey="Yeldandi V">V Yeldandi</name></author><author><name sortKey="Tong, Kb" uniqKey="Tong K">KB Tong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dodds Ashley, E" uniqKey="Dodds Ashley E">E Dodds-Ashley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ostermann, H" uniqKey="Ostermann H">H Ostermann</name></author><author><name sortKey="Solano, C" uniqKey="Solano C">C Solano</name></author><author><name sortKey="Jarque, I" uniqKey="Jarque I">I Jarque</name></author><author><name sortKey="Garcia Vidal, C" uniqKey="Garcia Vidal C">C Garcia-Vidal</name></author><author><name sortKey="Gao, X" uniqKey="Gao X">X Gao</name></author><author><name sortKey="Barrueta, Ja" uniqKey="Barrueta J">JA Barrueta</name></author><author><name sortKey="De Salas Cansado, M" uniqKey="De Salas Cansado M">M De Salas-Cansado</name></author><author><name sortKey="Stephens, J" uniqKey="Stephens J">J Stephens</name></author><author><name sortKey="Xue, M" uniqKey="Xue M">M Xue</name></author><author><name sortKey="Weber, B" uniqKey="Weber B">B Weber</name></author><author><name sortKey="Charbonneau, C" uniqKey="Charbonneau C">C Charbonneau</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Garcia, M" uniqKey="Garcia M">M Garcia</name></author><author><name sortKey="Marti, B" uniqKey="Marti B">B Marti</name></author><author><name sortKey="Ferro, B" uniqKey="Ferro B">B Ferro</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id><journal-title-group><journal-title>BMC Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26503366</article-id><article-id pub-id-type="pmc">4623895</article-id><article-id pub-id-type="publisher-id">1143</article-id><article-id pub-id-type="doi">10.1186/s12879-015-1143-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Auzinger</surname><given-names>Georg</given-names></name><address><email>georg.auzinger@nhs.net</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Playford</surname><given-names>E. Geoffrey</given-names></name><address><email>geoffrey_playford@health.qld.gov.au</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Graham</surname><given-names>Christopher N.</given-names></name><address><email>cgraham@rti.org</email></address><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author"><name><surname>Knox</surname><given-names>Hediyyih N.</given-names></name><address><email>hknox@rti.org</email></address><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author"><name><surname>Weinstein</surname><given-names>David</given-names></name><address><email>douvedel@yahoo.fr</email></address><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author"><name><surname>Kantecki</surname><given-names>Michal</given-names></name><address><email>Michal.Kantecki@Pfizer.com</email></address><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author"><name><surname>Schlamm</surname><given-names>Haran</given-names></name><address><email>HTSchlamm@att.net</email></address><xref ref-type="aff" rid="Aff5"></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Charbonneau</surname><given-names>Claudie</given-names></name><address><phone>+33 (0)1 58 07 30 23</phone><email>claudie.charbonneau@pfizer.com</email></address><xref ref-type="aff" rid="Aff4"></xref></contrib><aff id="Aff1"><label></label>King’s College Hospital, London, UK</aff><aff id="Aff2"><label></label>Princess Alexandra Hospital, Brisbane, Australia</aff><aff id="Aff3"><label></label>RTI Health Solutions, Research Triangle Park, Durham, NC USA</aff><aff id="Aff4"><label></label>Pfizer International Operations, Paris, France</aff><aff id="Aff5"><label></label>Pfizer Inc, New York, NY USA</aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>15</volume><elocation-id>463</elocation-id><history><date date-type="received"><day>18</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>23</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>© Auzinger et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines.</p></sec><sec><title>Methods</title><p>Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while patients categorised as clinical failures switched to a different antifungal class. Other inputs were all-cause mortality at 6 weeks, costs of treatment-related adverse events and other medical resource utilisation costs. Resource use was derived from the published literature and from discussion with clinical experts. Drug-acquisition/administration costs were taken from standard United Kingdom costing sources.</p></sec><sec><title>Results</title><p>The model indicated that first-line anidulafungin could be considered cost-effective versus fluconazole (incremental cost-effectiveness ratio £813 per life-year gained) for the treatment of C/IC. Anidulafungin was cost-saving versus caspofungin and micafungin due to lower total costs and a higher rate of survival combined with a higher probability of clinical success.</p></sec><sec><title>Discussion</title><p>European Society for Clinical Microbiology and Infectious Diseases guidelines recommend echinocandins for the first-line treatment of C/IC; our model indicated that anidulafungin marries clinical effectiveness and cost-effectiveness.</p></sec><sec><title>Conclusions</title><p>From the United Kingdom perspective, anidulafungin was cost-effective compared with fluconazole for the treatment of C/IC and was cost-saving versus the other echinocandins.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Anidulafungin</kwd><kwd>Candidaemia</kwd><kwd>Echinocandin</kwd><kwd>Invasive Candidiasis</kwd><kwd>Cost-Effectiveness</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc><affiliations><list><country><li>Australie</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Caroline du Nord</li><li>Grand Londres</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Paris</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Auzinger, Georg" sort="Auzinger, Georg" uniqKey="Auzinger G" first="Georg" last="Auzinger">Georg Auzinger</name></region></country><country name="Australie"><noRegion><name sortKey="Playford, E Geoffrey" sort="Playford, E Geoffrey" uniqKey="Playford E" first="E. Geoffrey" last="Playford">E. Geoffrey Playford</name></noRegion></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Graham, Christopher N" sort="Graham, Christopher N" uniqKey="Graham C" first="Christopher N." last="Graham">Christopher N. Graham</name></region><name sortKey="Knox, Hediyyih N" sort="Knox, Hediyyih N" uniqKey="Knox H" first="Hediyyih N." last="Knox">Hediyyih N. Knox</name><name sortKey="Schlamm, Haran" sort="Schlamm, Haran" uniqKey="Schlamm H" first="Haran" last="Schlamm">Haran Schlamm</name></country><country name="France"><region name="Île-de-France"><name sortKey="Weinstein, David" sort="Weinstein, David" uniqKey="Weinstein D" first="David" last="Weinstein">David Weinstein</name></region><name sortKey="Charbonneau, Claudie" sort="Charbonneau, Claudie" uniqKey="Charbonneau C" first="Claudie" last="Charbonneau">Claudie Charbonneau</name><name sortKey="Kantecki, Michal" sort="Kantecki, Michal" uniqKey="Kantecki M" first="Michal" last="Kantecki">Michal Kantecki</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001091 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 001091 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:4623895
|texte= Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:26503366" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |